URB937 – 100 mg

Brand:
Cayman
CAS:
1357160-72-5
Storage:
-20
UN-No:
Non-Hazardous - /

URB937 is a potent fatty acid amide hydrolase (FAAH) inhibitor (IC50 = 26.8 nM, in vitro) that does not penetrate the blood-brain barrier, thus preventing arachidonoyl ethanolamide (AEA; Item No. 90050) deactivation only in peripheral tissues.{18772} Its ED50 value for FAAH inhibition in brain is 200-fold higher than the ED50 value for FAAH inhibition in liver when administered systemically in mice (40 mg/kg versus 0.2 mg/kg, respectively). Subcutaneous administration of URB937 reduces acetic acid-induced writhing in mice with an ED50 value of 0.1 mg/kg. A single 1 mg/kg injection of URB937 sufficiently attenuates behavioral responses elicited in mouse models of neuropathic and inflammatory pain. As a peripherally-specific FAAH inhibitor, URB937 may offer an alternative approach to pain therapy devoid of unwanted central effects.  

 

Available on backorder

SKU: 10674 - 100 mg Category:

Description

A potent FAAH inhibitor (IC50 = 26.8 nM, in vitro; ED50 = 0.2 mg/kg in mouse liver); prevents AEA deactivation only in peripheral tissues; effective against neuropathic and inflammatory pain in mouse models


Formal name: N-cyclohexyl-carbamic acid, 3′-(aminocarbonyl)-6-hydroxy[1,1′-biphenyl]-3-yl ester

Synonyms: 

Molecular weight: 354.4

CAS: 1357160-72-5

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Fatty Acid Metabolism||Research Area|Immunology & Inflammation||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids||Research Area|Neuroscience|Pain Research